Stryker Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Stryker Corporation trades at $345.13 (market cap $133.54B), while Vertex Pharmaceuticals Incorporated trades at $524.62 (market cap $134.25B). The key difference: Stryker Corporation and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Stryker Corporation pays a 1.01% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SYK | VRTX | |
|---|---|---|
Market Cap | $133.54B | $134.25B |
Sector | Technology | Health |
52-Week High | $394.34 | $529.65 |
52-Week Low | $282.58 | $376.62 |
Enterprise Value | $145.01B | $128.37B |
Dividend Yield | 1.01% | — |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $341.17, down 1.34% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $379.44. The company reported strong Q2 2026 results with a 9% organic sales growth and an EPS beat, recovering from a Q1 cyber incident. Profitability remains robust with a net income margin of 14.43% and a dividend yield supported by recent increases.
The stock offers upside potential driven by earnings momentum and product innovation like Mako RPS, but risks include competitive pressures and past cybersecurity disruptions. Analyst sentiment is strongly bullish with 74% buy ratings, though valuation multiples like a P/E of 36.08 suggest premium pricing relative to historical norms.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Trailing returns across standard periods
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →